Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug trial halted early – what we know

NCT ID NCT06171789

Terminated Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PRO1107 (GEN1107)
What this could lead to
If successful, PRO1107 could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This trial was terminated early, so results are limited. It is an early-phase study with a small number of participants, so safety and effectiveness are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm gastroesophageal cancer non-small cell lung carcinoma ovarian cancer transitional cell carcinoma triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER GASTROESOPHAGEAL CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER TRIPLE NEGATIVE BREAST CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

  • Florida Cancer Specialists

    Sarasota, Florida, 34236, United States

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • Institution of Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Mountain Cancer Center

    Salt Lake City, Utah, 78229, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.